Background: Previous research has shown that many people experience a temporary worsening of mood following acute tryptophan depletion (ATD) and that concurrent use of serotonergic medications may influence such mood responses. We investigated mood and other consequences of ATD in women with bulimia nervosa who were or were not using concurrent serotonergic medications compared with women without bulimia.
Methods: Women self-referred for treatment of bulimia who were either not currently using psychoactive medications (n = 26) or who were using serotonin reuptake inhibitor medications exclusively (n = 13), as well as medication-free normal-eater control women (n = 25) completed interviews and questionnaires assessing eating and comorbid psychopathology and then participated in an ATD procedure involving balanced and tryptophan-depleted conditions.
Results: In the tryptophan-depleted condition, the groups displayed similar and significant decrements in plasma tryptophan levels and mood. Women with bulimia who were using serotonin reuptake inhibitors, but not the other groups, also reported an increased urge to binge eat in the tryptophan-depleted condition.
Limitations: Application of medication in participants with bulimia was not random.
Conclusion: Acute reductions in serotonin availability produced similar mood-reducing effects in bulimic and nonbulimic women. To the extent that ATD affected subjective experiences pertinent to eating (i.e., urge to binge eat), such effects appeared to depend upon ATD-induced competition with the therapeutic effects of serotonergic medications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732744 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the risk of mild serotonin syndrome in primary care: a retrospective case series of patients with treatment-resistant depression.
AME Case Rep
November 2024
Faculty of Medicine, Imperial College London, London, UK.
Background: Serotonin syndrome is an adverse drug reaction characterised by the excess of serotonin activity in the central nervous system. It is a condition of great concern in primary care where some patients, usually with treatment-resistant depression, get treatment with multiple serotonergic agents.
Case Description: This retrospective case series looked at 20 primary care patients with treatment-resistant depression who developed mild serotonin syndrome after starting a second antidepressant.
Social group size alters social behavior and dopaminergic and serotonergic systems.
Soc Neurosci
January 2025
Department of Food Science and Nutrition, Daegu Catholic University, Gyeongsan, Republic of Korea.
Social behavior is affected by social structure type, but how neural function changes with social type remains unclear. We investigated whether social group size affects social behaviors based on dopamine (DA) and serotonin (5-HT) systems. Four-week-old male mice were housed under different social group sizes: one, two, four, and eight mice per cage (1mpc, 2mpc, 4mpc, 8mpc, respectively).
View Article and Find Full Text PDFThe Influence of Serotonergic Signaling on Quality of Life, Depression, Insomnia, and Hypoxia in Obstructive Sleep Apnea Patients: Cross-Sectional Study.
J Clin Med
January 2025
Department of Sleep Medicine and Metabolic Disorder, Medical University of Lodz, 6/8 Mazowiecka, 92-215 Lodz, Poland.
: Serotonin and the serotonin transporter (SERT) may have a multifaceted, but not fully understood, role in obstructive sleep apnea (OSA) and its impact on mental health in this group of patients. This study aimed to investigate changes in serotonin and the serotonin transporter (SERT) and their association with depressive and insomnia symptoms. : This study included 76 participants (OSA group: = 36, control group (CG): = 40) who underwent polysomnography, while venous blood samples (evening and morning) were analyzed for serotonin and the SERT using ELISA.
View Article and Find Full Text PDFImaging the Brainstem Raphe in Medication-Overuse Headache: Pathophysiological Insights and Implications for Personalized Care.
Biomedicines
January 2025
Department of Neurology, University Medicine Greifswald, 17489 Greifswald, Germany.
: Medication-overuse headache (MOH) is a disabling condition affecting patients with chronic migraine resulting from excessive use of acute headache medication. It is characterized by both pain modulation and addiction-like mechanisms involving the brainstem raphe, a region critical to serotonergic signaling. This study investigates whether alterations in the brainstem raphe, assessed via transcranial sonography (TCS), are associated with MOH and independent of depressive symptoms, aiming to explore their utility as a biomarker.
View Article and Find Full Text PDFExploring Serotonin-1A receptor function in the effects of buspirone on cognition by molecular receptor expression and EEG analytical studies.
Eur J Pharmacol
January 2025
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.
Buspirone, a commonly prescribed medication for generalized anxiety disorder (GAD), is gaining attention for its narrow window of side effects such as lack of physical dependence, non-sedative properties as compared to other anxiolytic drugs. Its dose-specific therapeutic effects beyond anxiety highlights its clinical significance. Pharmacologically, buspirone activates serotonin-1A pre-synaptic autoreceptors and post-synaptic heteroreceptors which modulate serotonergic neurotransmission induced behavioral changes such as anxiolytic and nootropic effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!